Member Info for Marty130

Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.

To turn this around as the share price will continue to new lows.. Wake up BoD, pull your fingers out..

Pumped and dumped..

And then into into the 20s..

I was aware the conference was taking place, just a little disappointed the BoD didn't confirm attendance, as immupharma have..

IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™

12-14 January 2026 | San Francisco

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and the Biotech Showcase from 12-14 January 2026, in San Francisco, USA.

The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors.

Yanks have plenty of their own engineers.. One of the wells, though, was originally BP/shell owned

Onwards and upwards..

How do you mean? I have been on to trial a drug for asthma, I was paid 10 thousand, to take part.. HCTs are just another term used for trialling drugs or therapies..

Outlook for 2026: Management has indicated expectations for "high-single-digit revenue expansion" in 2026, with a return to group profitability forecast for 2027. This is supported by a robust sales pipeline and the integration of the acquired Clinical Research Services (CRS) business in Germany, which is expected to become "earnings accretive in 2026".

Recent Developments:

HVO announced that its CRS subsidiary secured new contracts worth over £5 million in late 2025.

The company is attending the J.P. Morgan Healthcare Week conference from January 12-15, 2026, in San Francisco.

The diversification strategy has broadened hVIVO's offerings beyond human challenge trials to include a full suite of early phase Contract Research Organisation (CRO) services.

Thanks. I'll look out for the red dot..

???

Someone explain what the hell is 'red dot day'?

Options trading is available in the UK through several brokers, primarily via two methods: trading listed options directly, or speculating on option prices using financial derivatives like Contracts for Difference (CFDs) and spread betting.

Anyone on here taken out any options with this stock?

If you look more carefully they have 70 million in cash. So no problems I regard to cash burn..

You didn't ask! But you suggested I was over exposed. I have a wide portfolio, rank, global data, kier, amongst others

..

Yamin "Mo" Khan, CEO of hVIVO since 2021, has a track record of driving significant revenue growth, achieving record EBITDA margins, and leading a strategic expansion of the company's services and facilities.

Career Background

Mo Khan has over 25 years of experience in clinical research and the Contract Research Organisation (CRO) industry. Before becoming CEO of hVIVO, he held various leadership positions within the sector.

Key Achievements and Track Record at hVIVO

Under Mo Khan's leadership, hVIVO has achieved several key milestones, transforming the business into a global leader in human challenge trials and laboratory services:

Financial Growth: The company has consistently reported record financial results.

2023: Revenue increased by 16% to £56.0 million, and EBITDA rose by 44% to £13.0 million.

2024: Revenue grew by nearly 12% to £62.7 million, with an industry-leading EBITDA margin of 26%.

2025 Outlook: The company targets £73 million in revenue, with a long-term goal of reaching £100 million in revenue by 2028.

Operational Expansion and Efficiency:

Oversaw the move to a new, purpose-built, 50-bed human challenge facility in Canary Wharf, which allowed for the handling of CL3 level pathogens and improved operational efficiency.

Achieved a record number of inoculations in 2024 across nine challenge trials.

Launched the FluCamp volunteer and patient recruitment service, which efficiently recruited 817 participants for its largest field trial to date.

Strategic Acquisitions and Diversification:

Led the €10 million acquisition of two clinical research units in Germany from CRS, adding 120 beds and expanding hVIVO's offerings into Phase I and Phase II trials in new therapeutic areas like cardio-metabolic and dermatology.

Acquired Cryostore for bio-specimen storage, enhancing hVIVO's end-to-end service capabilities.

Diversified the company's challenge models to include Omicron and hMPV (human metapneumovirus).

Investor Confidence:

The company has maintained a strong cash position and confirmed continued dividend payments.

Mo Khan and other directors have publicly purchased company shares, signaling confidence in the company's growth strategy.

Mo Khan's leadership is widely reported to be the driving force behind hVIVO's "record-breaking performance" and strategic vision for future growth.

Https://www.proactiveinvestors.co.uk/companies/news/1084331/broker-backs-hvivo-2026-rebound-1084331.html

So you are short stock presumably, as a rising price is detrimental to your current investment

strategy..